Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study

Detalhes bibliográficos
Autor(a) principal: Morais, Ana Heloneida de Araújo
Data de Publicação: 2019
Outros Autores: Matias, Lidia Leonize Rodrigues, Costa, Rafael Oliveira de Araújo, Passos, Thais Souza, Queiroz, Jaluza Luana Cravalho de, Serquiz, Alexandre Coelho, Maciel, Bruna Leal Lima, Santos, Pedro Paulo de Andrade, Camillo, Cristina da Silva, Gonçalves, Catarina, Amado, Izabel Rodriguez, Pastrana, Lorenzo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRN
Texto Completo: https://repositorio.ufrn.br/handle/123456789/54725
Resumo: In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia
id UFRN_b7499b6e050e345ed7f4df12003e5eca
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/54725
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Morais, Ana Heloneida de AraújoMatias, Lidia Leonize RodriguesCosta, Rafael Oliveira de AraújoPassos, Thais SouzaQueiroz, Jaluza Luana Cravalho deSerquiz, Alexandre CoelhoMaciel, Bruna Leal LimaSantos, Pedro Paulo de AndradeCamillo, Cristina da SilvaGonçalves, CatarinaAmado, Izabel RodriguezPastrana, Lorenzohttps://orcid.org/0000-0002-6460-911X2023-09-06T19:57:20Z2023-09-06T19:57:20Z2019MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023.https://repositorio.ufrn.br/handle/123456789/5472510.3390/nu11112770NutrientsTamarindusindica L.encapsulationoverfeedingdigestionfasting glucoseinsulinTamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleIn vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemiaengreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNinfo:eu-repo/semantics/openAccessORIGINALTamarindTrypsin_Matias_2019.pdfTamarindTrypsin_Matias_2019.pdfapplication/pdf6327752https://repositorio.ufrn.br/bitstream/123456789/54725/1/TamarindTrypsin_Matias_2019.pdfffd8a7bab377ffc1d3641e4f9d6701d2MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81484https://repositorio.ufrn.br/bitstream/123456789/54725/2/license.txte9597aa2854d128fd968be5edc8a28d9MD52123456789/547252023-09-06 16:57:20.717oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2023-09-06T19:57:20Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.pt_BR.fl_str_mv Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
spellingShingle Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
Morais, Ana Heloneida de Araújo
Tamarindusindica L.
encapsulation
overfeeding
digestion
fasting glucose
insulin
title_short Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_full Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_fullStr Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_full_unstemmed Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_sort Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
author Morais, Ana Heloneida de Araújo
author_facet Morais, Ana Heloneida de Araújo
Matias, Lidia Leonize Rodrigues
Costa, Rafael Oliveira de Araújo
Passos, Thais Souza
Queiroz, Jaluza Luana Cravalho de
Serquiz, Alexandre Coelho
Maciel, Bruna Leal Lima
Santos, Pedro Paulo de Andrade
Camillo, Cristina da Silva
Gonçalves, Catarina
Amado, Izabel Rodriguez
Pastrana, Lorenzo
author_role author
author2 Matias, Lidia Leonize Rodrigues
Costa, Rafael Oliveira de Araújo
Passos, Thais Souza
Queiroz, Jaluza Luana Cravalho de
Serquiz, Alexandre Coelho
Maciel, Bruna Leal Lima
Santos, Pedro Paulo de Andrade
Camillo, Cristina da Silva
Gonçalves, Catarina
Amado, Izabel Rodriguez
Pastrana, Lorenzo
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.authorID.pt_BR.fl_str_mv https://orcid.org/0000-0002-6460-911X
dc.contributor.author.fl_str_mv Morais, Ana Heloneida de Araújo
Matias, Lidia Leonize Rodrigues
Costa, Rafael Oliveira de Araújo
Passos, Thais Souza
Queiroz, Jaluza Luana Cravalho de
Serquiz, Alexandre Coelho
Maciel, Bruna Leal Lima
Santos, Pedro Paulo de Andrade
Camillo, Cristina da Silva
Gonçalves, Catarina
Amado, Izabel Rodriguez
Pastrana, Lorenzo
dc.subject.por.fl_str_mv Tamarindusindica L.
encapsulation
overfeeding
digestion
fasting glucose
insulin
topic Tamarindusindica L.
encapsulation
overfeeding
digestion
fasting glucose
insulin
description In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia
publishDate 2019
dc.date.issued.fl_str_mv 2019
dc.date.accessioned.fl_str_mv 2023-09-06T19:57:20Z
dc.date.available.fl_str_mv 2023-09-06T19:57:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023.
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/handle/123456789/54725
dc.identifier.doi.none.fl_str_mv 10.3390/nu11112770
identifier_str_mv MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023.
10.3390/nu11112770
url https://repositorio.ufrn.br/handle/123456789/54725
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nutrients
publisher.none.fl_str_mv Nutrients
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/54725/1/TamarindTrypsin_Matias_2019.pdf
https://repositorio.ufrn.br/bitstream/123456789/54725/2/license.txt
bitstream.checksum.fl_str_mv ffd8a7bab377ffc1d3641e4f9d6701d2
e9597aa2854d128fd968be5edc8a28d9
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1814833003349671936